Showing 35,225 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

PrEP

PrEP options Video

October 2022
Injectable & long-acting PrEP

European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention

Editor's pick
ViiV press release
28 October 2022
Mpox

Monkeypox outbreak is ebbing—but why exactly?

Editor's pick
Science
28 October 2022
Antibody-based treatment

GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes long-acting combo trial

Editor's pick
FierceBiotech
28 October 2022
HIV & criminal law

Lesotho high court finds imposition of death sentence solely on the basis of HIV status unconstitutional

Editor's pick
HIV Justice Network
27 October 2022
Mpox

Most Hospitalized Monkeypox Patients in the U.S. Were H.I.V.-Positive

Editor's pick
The New York Times
27 October 2022
Side effects

CD4 and white blood cell declines caused by islatravir are dose-related and reversible, but rule out using it for prevention

News
27 October 2022
Confidentiality, consent & medical ethics

US: Presidential Advisory Council on HIV/AIDS issues resolution on Molecular HIV Surveillance and Cluster Detection

Editor's pick
HIV Justice Network
26 October 2022
Starting treatment

Long-Term Results Confirm Benefits of Early HIV Treatment

Editor's pick
POZ
26 October 2022
Antibody-based treatment

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

Editor's pick
ViiV press release
26 October 2022
Coronavirus

Age, Immune Conditions, Comorbidities Drive Severe COVID Risk After Vaccination

Editor's pick
NATAP
26 October 2022
People with limited treatment options

Lenacapavir: 75% Sub-50 Response at 52 Weeks Despite Heavy ART Experience

Editor's pick
NATAP
26 October 2022
Cardiovascular disease

High blood pressure and HIV

About HIV
October 2022
Sexually transmitted infections prevention

San Francisco pioneers rollout of new STI prevention tool

Editor's pick
Bay Area Reporter
26 October 2022
PrEP programmes & uptake

Rapid scale-up of PrEP in Ukraine this year, despite the war

News
26 October 2022
Cardiovascular disease

People with HIV not getting medication to prevent heart disease, despite high risk

News
25 October 2022
Migrants, refugees & displaced people

So far, Poland has seen fewer Ukrainian refugees with HIV than expected

News
25 October 2022
Adherence

Tips to help you take your HIV medication (adherence) Video

October 2022
PrEP

PrEP Awareness and Misconceptions Among Cisgender Women: Findings From IDWeek

Editor's pick
TheBodyPro
24 October 2022
Combatting stigma

aidsmapWOMEN: Self-empowerment against HIV stigma Video

October 2022
Sexually transmitted infections prevention

Efficacy of a Meningococcal B Vaccine and a Preventive Antibiotic in Reducing the Risk of Sexually Transmitted Infections

Editor's pick
ANRS
24 October 2022
Improving HIV care

Fix the HIV Care Continuum, Extend the Lives of Black MSM

Editor's pick
TheBodyPro
24 October 2022
Mpox

Monkeypox Treatment Trial Begins in the Democratic Republic of the Congo

Editor's pick
POZ
24 October 2022
Hepatitis B

Three-Dose Hepatitis B Vaccine Regimen Protects People With HIV

Editor's pick
POZ
21 October 2022